TURKISH JOURNAL OF UROLOGY, cilt.33, sa.4, ss.411-415, 2007 (ESCI)
Introduction: Surrogate end points are needed in prediction of prognosis in hormone resistant prostate cancer (HRCP). Initial PSA value, Gleason score, extent of metastatic spread and number of metastases have been used for this purpose with limited value. PSA doubling time (DTPSA) has been used in defining the prognosis in prostate cancer and initial results have been hopeful. In this study we analyzed the relationship between DTPSA and patient survival in a cohort of HRPC patients.